← Back to search
2maw

NMR structures of the alpha7 nAChR transmembrane domain.

Method: SOLUTION NMR Dmax: 70.3 Å Quality: REASONABLE
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Neuronal acetylcholine receptor subunit alpha-7

Homo sapiens

UniProt P36544

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count Chain A； UniProt 228–326 Chain A； UniProt 467–496 Fragment：UNP residues 141-235, transmembrane domain Mutation：A195S, V200S, L202S No other associated polymer SOLUTION NMR NMR measurement conditions：pH 4.7；318 K；Ionic strength (raw mmCIF value) 0.01；Pressure ambient NMR sample composition：0.25 mM [U-100% 13C; U-100% 15N] protein, 95% H2O/5% D2O | 95% H2O/5% D2O Resolution not provided

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 2MAW Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
7EKI human alpha 7 nicotinic acetylcholine receptor in apo-form Deposited 2021-04-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.18 Å
7EKP human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 Deposited 2021-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded I33 7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.85 Å
7EKT human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 and PNU-120596 Deposited 2021-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 I33 7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.02 Å
7KOO Alpha-7 nicotinic acetylcholine receptor bound to alpha-bungarotoxin in a resting state Deposited 2020-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
7KOQ Alpha-7 nicotinic acetylcholine receptor bound to epibatidine in a desensitized state Deposited 2020-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
7KOX Alpha-7 nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 in the activated state Deposited 2020-11-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.70 Å
7RPM Structures of the Intracellular Domain and Transmembrane Domain of the Human alpha7 Nicotinic Acetylcholine Receptors Deposited 2021-08-03 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain B 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain C 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain D 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain E 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR sample composition 0.24 mM [U-13C; U-15N] alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] S358C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 20 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C427-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.28 mM V311C-MTSL alpha7 TMD-ICD, 0.07 mM [U-15N] V311C alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM C427-MTSL alpha7 TMD-ICD, 0.06 mM [U-15N] C427 alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.28 mM V311C alpha7 TMD-ICD, 0.07 mM [U-15N] V311C-MTSL alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM C427 alpha7 TMD-ICD, 0.06 mM [U-15N] C427-MTSL alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C427-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C427-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C317-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C317-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] C219-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C219-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.35 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.35 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C317-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
8C9X human alpha7 nicotinic receptor in complex with the C4 nanobody Deposited 2023-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8CAU human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine Deposited 2023-01-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–502（479 aa）
Chain B 24–502（479 aa）
Chain C 24–502（479 aa）
Chain D 24–502（479 aa）
Chain E 24–502（479 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
8CE4 Human alpha7 nicotinic receptor in complex with the E3 nanobody Deposited 2023-02-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.70 Å
8CI1 Human alpha7 nicotinic receptor in complex with the E3 nanobody and nicotine Deposited 2023-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.80 Å
8CI2 human alpha7 nicotinic receptor in complex with the C4 nanobody under sub-saturating conditions Deposited 2023-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.40 Å
8F4V Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state Deposited 2022-11-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain B 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain C 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain D 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain E 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E IVM (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside × 5 SOLUTION NMR
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 % [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 0.1 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 240 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 30 uM PNU, 0.2 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 100 uM ivermectin, 0.3 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.55 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.95 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.20 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
8P1H Crystal structure of the chimera of human 14-3-3 zeta and phosphorylated cytoplasmic loop fragment of the alpha7 acetylcholine receptor Deposited 2023-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 361–372（12 aa）
Chain B 361–372（12 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) EDO 1,2-ETHANEDIOL × 4 AZI AZIDE ION × 3 BEZ BENZOIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；288 K；0.2 M Magnesium acetate tetrahydrate; 0.1 M Sodium cacodylate trihydrate pH 6.5; 20% w/v Polyethylene glycol 8,000
Resolution 1.95 Å R-free 0.253
8UT1 Alpha7-nicotinic acetylcholine receptor bound to epibatidine Deposited 2023-10-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8UTB Alpha7-nicotinic acetylcholine receptor bound to epibatidine and NS-1738 Deposited 2023-10-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded XG3 N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl]urea × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 EPJ EPIBATIDINE × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8UZJ Alpha7-nicotinic acetylcholine receptor bound to epibatidine and ivermectin Deposited 2023-11-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 IVM (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8V80 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and (-)-TQS Deposited 2023-12-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 YLR (3aR,4S,9bS)-4-(naphthalen-1-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.34 Å
8V82 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 Deposited 2023-12-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.61 Å
8V86 Alpha7-nicotinic acetylcholine receptor bound to GAT107 Deposited 2023-12-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.47 Å
8V88 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and GAT107 Deposited 2023-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8V89 Alpha7-nicotinic acetylcholine receptor time resolved resting state Deposited 2023-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 R16 HEXADECANE × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
8V8A Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 desensitized intermediate state Deposited 2023-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.19 Å
8V8C Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 1 Deposited 2023-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 CA CALCIUM ION × 3 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.29 Å
8V8D Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 2 Deposited 2023-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 CA CALCIUM ION × 3 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.31 Å
9IIR human alpha 7 nicotinic acetylcholine receptor in complex with GAT107 and calcium (desensitized state) Deposited 2024-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.93 Å
9IIV human alpha 7 nicotinic acetylcholine receptor in complex with GAT107 and calcium (open state) Deposited 2024-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.89 Å
9J37 Cryo-EM structure of human Alpha-7 nicotinic acetylcholine receptor Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 23–502（480 aa）
Chain B 23–502（480 aa）
Chain C 23–502（480 aa）
Chain D 23–502（480 aa）
Chain E 23–502（480 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.30 Å
9LH5 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (open state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.61 Å
9LH6 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (five-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.69 Å
9LH8 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (four-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 4 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.74 Å
9LH9 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (ortho-three-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.98 Å
9LHA human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (meta-three-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.96 Å
9LHB human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (ortho-two-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.11 Å
9LHC human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (meta-two-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.17 Å
9LHD human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (one-nicotine-bound desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.24 Å
9LHE human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (nicotine-free desensitized state) Deposited 2025-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.25 Å
9LN7 Alpha-7 nicotinic acetylcholine receptor bound to inhibitory bicyclic peptide KP2007 in a resting state. Deposited 2025-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 1–502（502 aa）
Chain C 1–502（502 aa）
Chain E 1–502（502 aa）
Chain G 1–502（502 aa）
Chain I 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.94 Å
9NX0 Alpha7-nicotinic acetylcholine receptor bound to conotoxin ImI Deposited 2025-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–501（478 aa）
Chain B 24–501（478 aa）
Chain C 24–501（478 aa）
Chain D 24–501（478 aa）
Chain E 24–501（478 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.06 Å
9NX1 Alpha7-nicotinic acetylcholine receptor bound to conotoxin ImII Deposited 2025-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain B 24–501（478 aa）
Chain C 24–501（478 aa）
Chain D 24–501（478 aa）
Chain E 24–501（478 aa）
Chain F 24–501（478 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
9QTN Human alpha7 nicotinic receptor in complex with the F1 nanobody Deposited 2025-04-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–502（479 aa）
Chain B 24–502（479 aa）
Chain C 24–502（479 aa）
Chain D 24–502（479 aa）
Chain E 24–502（479 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.28 Å
9QTO Human alpha7 nicotinic receptor in complex with the E6 nanobody Deposited 2025-04-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 10 PDB declaration: decameric
Chain A 24–349（326 aa）
Chain B 24–349（326 aa）
Chain C 24–349（326 aa）
Chain D 24–349（326 aa）
Chain E 24–349（326 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.16 Å
9VIQ human alpha 7 nicotinic acetylcholine receptor L277A mutant in complex with L-nicotine (desensitized state) Deposited 2025-06-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Mutation：L277A Mutation：L277A Mutation：L277A Mutation：L277A Mutation：L277A NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.24 Å
9VIX human alpha 7 nicotinic acetylcholine receptor L278A mutant in complex with L-nicotine (desensitized state) Deposited 2025-06-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Mutation：L278A Mutation：L278A Mutation：L278A Mutation：L278A Mutation：L278A NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.06 Å

44 other PDB entries and 44 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name ACHA7_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 4–102； UniProt 228–326 Author chain A； PDBConstruct 108–137； UniProt 467–496

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 2maw

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 2maw
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id2maw
Deposition date deposition_date2013-07-19
Structure title titleNMR structures of the alpha7 nAChR transmembrane domain.
Keywords keywordstransmembrane domain, MEMBRANE PROTEIN; MEMBRANE PROTEIN
Experimental Method methodSOLUTION NMR
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier18.47 Å
Radius of gyration Rg (electron density) rg_electron17.76 Å
Forward intensity I(0) i0940534000.00
Molecular weight molecular_weight285520.0 kDa
Excluded volume excluded_volume367300 ų
Envelope volume envelope_volume43189 ų
Hydration-shell volume shell_volume18077 ų
Envelope diameter envelope_diameter74.4 Å
Shell Rg shell_rg27.03 Å
Envelope Rg envelope_rg21.84 Å
Shape Rg shape_rg17.84 Å
Total Rg total_rg17.65 Å
Total atoms total_atoms40620
Residues n_residues2680
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax70.3 Å
Rg (real space) rg_real18.71 Å
Rg uncertainty (real space) rg_real_error0.81 Å
I(0) (real space) i0_real9.4050e+08
I(0) uncertainty (real space) i0_real_error1.3270e+07
Rg (reciprocal space) rg_reciprocal18.68 Å
I(0) (reciprocal space) i0_reciprocal940500000.0000
Solution quality estimate total_estimate0.6611
Solution quality rating solution_quality REASONABLE a REASONABLE solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary16.4 Å
Skewness Skewness skewness0.604
Kurtosis Kurtosis kurtosis-0.213
Angular range angular_range— – 0.4300 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha752000.0000
Real-space data points n_real_points74
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.103; Stabil: 0.992; Sysdev: 1.000; Positv: 1.000; Valcen: 0.316; Smooth: 0.988
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (1)

▼

7. Fold Classification (SCOP + CATH) 1 domains

CATH v4.4 (1 domains)

Domain ID domain_id2mawA00
Class class1 — Mainly Alpha
Architecture architecture20 — Up-down Bundle
Topology topology58 — Methane Monooxygenase Hydroxylase; Chain G, domain 1
Homologous superfamily homologous superfamily390 — Neurotransmitter-gated ion-channel transmembrane domain
▶

8. Citations (1)

▶

9. Files and Curves (10)